It is interesting that the manufacturer of the nasal spray flu vaccine had some problems back in 2007.

As noted by the Washington Post on May 30, 2007 (article here),

The Food and Drug Administration said yesterday that its investigators found contamination problems with the manufacturing process of MedImmune’s nasal flu vaccine FluMist but that the finished product was not affected.

Apparently the problems had to do with mold and bacteria, and steps to prevent contamination, and, according to the article,

The FDA’s letter cited “significant deviations from current good manufacturing practice.”

It does appear that the problems were rectified at that time, given developments noted below.

Back then, it was noted that

Expanding the product’s market to children under 5 has been a cornerstone of MedImmune’s efforts to revive FluMist, which has failed to catch on in the marketplace. It is now approved only for people ages 5 to 49.

It seems that this  effort was successful, because currently the nasal spray is approved for children above the age of 2.

Nevertheless, recent news that the injected version appears to work much better in adults than the inhaled spray does not augur well for the company.  The jury is still out on the difference in efficacy for children, but the same observations I made for adults apply to children.  People are pretty used to shots, even if they don’t like them.  All in all, this nasal spray idea sounds better in theory than in practice.  Parents must endure their kids’ getting lots of shots by injection, and one more really isn’t going to make that much difference, I don’t think.